Founded in 2024 out of the University of Strasbourg, Albupad engineers a proprietary platform that stabilises native albumin to create drug-delivery systems capable of releasing biologic medicines over extended periods. The technology targets chronic illnesses and oncology indications where sustained dosing can improve efficacy and patient compliance. Albupad’s approach aims to integrate seamlessly into existing pharmaceutical pipelines, offering partners turn-key formulations rather than standalone drugs. The company estimates the addressable global market for long-acting biologics exceeds €400 billion. Proceeds from its latest raise will fund prototype development and advance regulatory preparations. Although still pre-revenue, Albupad is positioning itself as an enabling technology provider to large pharma and biotech firms.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2026